



## **GE Introduces Discovery™ STE, A Breakthrough in PET/CT Imaging**

### **New Molecular Imaging System Offers Physicians Enhanced Clinical Performance for Advanced Applications**

**Düsseldorf, November 16th, 2005** - GE Healthcare introduced today Discovery™ STE, the latest addition to the company's market leading modular PET/CT platform, at the 2005 European Association of Nuclear Medicine (EANM) in Istanbul. The new Discovery STE provides physicians with a wide range of clinically relevant capabilities and true hybrid imaging flexibility that will help them to earlier and better stage patients with cancer, heart disease, and neurological conditions and to monitor a patient's course of treatment. GE was the first to commercially introduce PET/CT imaging in 2001, an advanced technology that integrates a Positron Emission Tomography (PET) system with a Computed Tomography (CT) system. To date, more than 500 GE Discovery PET/CT systems have been installed at medical facilities worldwide. Moreover, for the recently launched Discovery STE, the first two systems have now been installed in Europe.

The new Discovery STE system is an elite clinical performance configuration, built on the foundation of Discovery ST. Discovery STE delivers a balanced system design of high sensitivity, resolution and count-rate performance. **Its powerful processing & acquisition capabilities** make Discovery STE the ideal system for growing procedure demands in neurology and cardiology, without sacrificing the requirements of a premier oncology system.

"The scanner provides an incredible combination of performance specifications and acquisitions capabilities, one which compliments our tracer and clinical investigations," said Mika Teras Ph.D., senior physicist at Turku PET Center in Finland.

With the Discovery STE system, physicians are provided clinically relevant choices to image a broad range of patient population with a variety of clinical conditions.

"Discovery STE provides the opportunity for us to ensure an excellent examination for any patient that enters our facility, regardless of their clinical imaging need," said Prof. Juhani Knuuti M.D., Director of Turku PET Center in Finland.

At the heart of the Discovery STE is the revolutionary Discovery Dimension hardware and software platform, fully integrated to optimize PET/CT workflow. The new Discovery Dimension platform provides a wider range of choices to meet patient's clinical needs, enabling clinicians to:

- **Acquire radiology prescription diagnostic IV Contrast CT images during the PET/CT study, so that patients are subjected to fewer exams and less dose.**



- **Tailor the CT X-ray dose to each patient**, a capability that can result in up to 40% less dose.
- **Simultaneously complete a static image and 4D motion study in one acquisition**, eliminating the need for multiple studies.
- Perform advanced image reconstruction techniques of 2D and 3D for **excellent image quality on every patient exam**
- **View completely reconstructed 2D and 3D images during the exam**. Allowing image review while the patient is still on the table, due to GE's new, patented **VUE Point** reconstruction.

"With these new clinical features, we are able to provide an examination tailored to the clinical needs of each individual patient," said Prof. Juhani Knuuti "VUE Point reconstruction has provided dramatic image quality improvement."

"The Discovery STE demonstrates GE's commitment to develop revolutionary technologies that provide doctors the opportunity to diagnose and manage treatment of an individual's medical condition earlier and better, while offering a continuum of field upgrades that will keep Discovery PET/CT users at the forefront of diagnostic imaging," said Hadi Moufarrej, general manager of global Functional Imaging for GE Healthcare.

#### **Über GE Healthcare:**

GE Healthcare liefert medizintechnische Lösungen, die einen wichtigen Beitrag zur Gestaltung des neuen Zeitalters für die Patientenversorgung leisten. Mit Hilfe des umfassenden Know-hows von GE Healthcare in den Bereichen medizinische Bildgebung und Informationstechnologien, medizinische Diagnostik, Patientenmonitoring, Krankheitsforschung, Arzneimittelforschung und biopharmazeutische Fertigungstechnologien sollen Krankheiten früher erkannt und individualisierte Arzneimitteltherapien entwickelt werden. GE Healthcare bietet ein breites Angebotsportfolio um die Produktivität im Gesundheitswesen zu steigern und ermöglicht eine verbesserte Diagnose, Behandlung und Überwachung von Patienten, die an Krebs, neurologischen oder Herz-Kreislauf-Erkrankungen leiden.

GE Healthcare ist ein Geschäftsbereich der General Electric Company (NYSE: GE) mit einem Umsatz von 15 Mrd. US\$ und Hauptgeschäftssitz in Großbritannien. Weltweit beschäftigt GE Healthcare über 43.000 Mitarbeiter, die Healthcare-Anbieter und ihre Patienten in über 100 Ländern weltweit bedienen. Weitere Informationen zu GE Healthcare finden Sie unter [www.gehealthcare.com](http://www.gehealthcare.com).

#### **Pressekontakt:**

**Rudolf Beyenburg**

**Tel: +49-212-280-2111**

**E-Mail: [Rudolf.Beyenburg@ge.com](mailto:Rudolf.Beyenburg@ge.com)**